JPS63258801A - Viral infection inhibitor for public bathhouse - Google Patents
Viral infection inhibitor for public bathhouseInfo
- Publication number
- JPS63258801A JPS63258801A JP9404987A JP9404987A JPS63258801A JP S63258801 A JPS63258801 A JP S63258801A JP 9404987 A JP9404987 A JP 9404987A JP 9404987 A JP9404987 A JP 9404987A JP S63258801 A JPS63258801 A JP S63258801A
- Authority
- JP
- Japan
- Prior art keywords
- group
- alkyl
- carbon atoms
- infection
- preventive agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000009385 viral infection Effects 0.000 title claims abstract description 12
- 239000003112 inhibitor Substances 0.000 title abstract 4
- 208000036142 Viral infection Diseases 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 32
- 208000015181 infectious disease Diseases 0.000 claims abstract description 25
- 239000004094 surface-active agent Substances 0.000 claims abstract description 15
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 9
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims abstract description 6
- 125000004945 acylaminoalkyl group Chemical group 0.000 claims abstract description 5
- 125000000129 anionic group Chemical group 0.000 claims abstract description 4
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims abstract description 4
- 125000000962 organic group Chemical group 0.000 claims abstract description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 28
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 230000003449 preventive effect Effects 0.000 claims description 15
- -1 halogen ion Chemical class 0.000 claims description 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 6
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 5
- 125000005041 acyloxyalkyl group Chemical group 0.000 claims description 4
- 150000008051 alkyl sulfates Chemical class 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 9
- 201000010099 disease Diseases 0.000 abstract description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 4
- 230000003612 virological effect Effects 0.000 abstract description 4
- 241000725303 Human immunodeficiency virus Species 0.000 abstract description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract description 2
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 239000000344 soap Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- 230000002265 prevention Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 5
- 239000008272 agar Substances 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000012678 infectious agent Substances 0.000 description 3
- 239000002736 nonionic surfactant Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 229960005475 antiinfective agent Drugs 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 125000001453 quaternary ammonium group Chemical group 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 210000001138 tear Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 208000035874 Excoriation Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000001204 arachidyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000531 effect on virus Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 125000002960 margaryl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000004264 monolayer culture Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005702 oxyalkylene group Chemical group 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- 125000002889 tridecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Description
【発明の詳細な説明】
［産業上の利用分野コ
本発明は公衆浴場用ウィルス感染防止剤、詳しくはソー
プランド、銭湯などの公衆浴場でのウィルス感染を防止
・予防するために用いられる薬剤（以下、感染防止剤と
略記）に関するものである。DETAILED DESCRIPTION OF THE INVENTION [Industrial Field of Application] The present invention relates to a virus infection preventive agent for public baths, specifically an agent used to prevent and prevent virus infections in public baths such as soaplands and public baths (hereinafter referred to as , infection prevention agent).
［従来の技術］
従来、ソープランド、銭湯などの公衆浴場でのウィルス
に対する感染防止は、はとんど取上げられていなかった
。[Prior Art] Conventionally, prevention of virus infection in public baths such as soaplands and public baths has not been taken up very much.
［発明が解決しようとする問題点］
最近、ウィルス疾患の有効な治療法の見出されていない
工、イズウィルスやヘルペスウィルスの保有者の増加か
ら、ウィルスの感染を防止する方法の確立が要望されて
いる。ソープランドではソープランド嬢と客との接触に
より、ウィルス感染者（もしくは保有者）と非感染者と
の体液（血液、精液、唾液、尿、涙など）交換によりウ
ィルス感染の虞れがあり、かかるウィルス感染の防止が
必要とされている。[Problems to be solved by the invention] Recently, there has been a need to establish a method to prevent virus infection due to the increase in the number of virus carriers and herpesviruses, for which no effective treatment has been found for viral diseases. has been done. At soaplands, there is a risk of virus infection due to the exchange of body fluids (blood, semen, saliva, urine, tears, etc.) between a virus infected person (or carrier) and a non-infected person due to contact between the soapland lady and the customer. Prevention of infection is needed.
［問題点を解決するための手段］
本発明者らは、このような公衆浴場におけるウィルス感
染の防止につき検討を重ねた結果、特定の界面活性剤が
感染防止に有効であることを見出し、本発明に到達した
。[Means for solving the problem] As a result of repeated studies on preventing virus infections in public baths, the present inventors discovered that a specific surfactant is effective in preventing infection, and developed the present invention. invention has been achieved.
すなわち、本発明は、一般式（１）で示される第４級窒
素原子含有界面活性剤からなる公衆浴“場用ウィルス感
染防止剤である。That is, the present invention is a virus infection preventive agent for public baths comprising a quaternary nitrogen atom-containing surfactant represented by the general formula (1).
（式中、Ｒ１は炭素数８〜２２のアルキル基を有する有
機基；Ｒ２はアルキル基、アルキル置換されていてもよ
いアラルキル基、アシルアミノアルキル基、アシロキシ
アルキル基、アルコキシアルキル基、アルキルポリオキ
シアルキレン基、またはアルキルアリルポリオキシアル
キレン基；Ｒ３゜Ｒ４は同一でも異なっていてもよい炭
素数１〜４のアルキル基、炭素数２〜４のヒドロキシア
ルキル基または炭素数７〜１４のアラルキル基：Ｘはア
ニオン性対イオンを表す。）
Ｒ１には、アルキル基、アシルアミノアルキル基（アル
キルアミドアルキル基）、アシロキシアルキル基および
アルコキシアルキル基が含まれ、式Ｒ−またはＲ−Ｚ−
Ａ−で示される基（式中Ｒは炭素数８〜２０のアルキル
基、Ｚは一〇〇ＮＨ−。(In the formula, R1 is an organic group having an alkyl group having 8 to 22 carbon atoms; R2 is an alkyl group, an aralkyl group that may be substituted with alkyl, an acylaminoalkyl group, an acyloxyalkyl group, an alkoxyalkyl group, an alkyl poly Oxyalkylene group or alkylaryl polyoxyalkylene group; R3゜R4 is an alkyl group having 1 to 4 carbon atoms, a hydroxyalkyl group having 2 to 4 carbon atoms, or an aralkyl group having 7 to 14 carbon atoms, which may be the same or different. :X represents an anionic counterion.) R1 includes an alkyl group, an acylaminoalkyl group (alkylaminoalkyl group), an acyloxyalkyl group, and an alkoxyalkyl group, and has the formula R- or R-Z-
A group represented by A- (in the formula, R is an alkyl group having 8 to 20 carbon atoms, and Z is 100NH-).
−ＣＯＯ−または−〇−：Ａは炭素数１〜４のアルキレ
ン基を示す。）が挙げられる。-COO- or -〇-: A represents an alkylene group having 1 to 4 carbon atoms. ).
上記各式中のＲとしては、炭素数８〜２０の、飽和また
は不飽和の、直鎖または側鎖を有する。アルキル基（脂
肪族炭化水素基）、たとえばオクチル、２−エチルヘキ
シル、ノニル、デシル、ドデシル、トリデシル、テトラ
デシル、オクタデシル。R in each of the above formulas has a saturated or unsaturated straight chain or side chain having 8 to 20 carbon atoms. Alkyl groups (aliphatic hydrocarbon groups) such as octyl, 2-ethylhexyl, nonyl, decyl, dodecyl, tridecyl, tetradecyl, octadecyl.
エイコシル、オレイル基：Ａとしてはエチレン。Eicosyl, oleyl group: A is ethylene.
プロピレン、ブチレン基が挙げられる。Examples include propylene and butylene groups.
Ｒ−Ｚ−Ａ−で示される基としては、アルキルアミドア
ルキル基たとえばステアラミドエチル基（Ｃ１７Ｈ３５
ＣＯＮＨＣＨ２ＣＨ２−）、ステアラミドプロピル基（
Ｃ１γＨ３５ＣＯＮＨＣＨ２ＣＨ２ＣＨ２−） ニアシ
ロキシアルキル基たとえばステアロイロキシメチル基：
アルコキシアルキル基たとえばステアリロキシメチル基
が挙げられる。Examples of the group represented by R-Z-A- include an alkylamidoalkyl group, such as a stearamideethyl group (C17H35
CONHCH2CH2-), stearamidopropyl group (
C1γH35CONHCH2CH2CH2-) Nearsiloxyalkyl group, such as stearoyloxymethyl group:
Alkoxyalkyl groups include, for example, stearyloxymethyl groups.
Ｒ２のアルキル基としては、上記（Ｒ＞のようなアルキ
ル基、および炭素数１〜７の、飽和または不飽和の、直
鎖または側鎖を有する。アルキル基たとえばメチル、エ
チル、ｎ−およびｉ−プロピル。The alkyl group for R2 is an alkyl group such as the above (R>), and a saturated or unsaturated straight chain or side chain having 1 to 7 carbon atoms.Alkyl groups such as methyl, ethyl, n- and i -Propyl.
ブチル、ヘキシル、プロペニル、ブテニル基：アルキル
置換されていてもよいアラルキルでいてもよいアラルキ
ル基としては、ベンジル基、および上記のようなアルキ
ル基で置換されたベンジル基；アシルアミノアルキル、
アシロキシアルキル、アルコキシアルキル基としては、
前述のようなＲ−Ｚ−Ａ−で示される基、およびＲが上
述の炭素数１−９のアルキル基で置き換わったもの：ア
ルキルポリオキシアルキル基、アルキルアリルポリオキ
シアルキル基としては、それぞれ式Ｒｓ （ＡＯ）ｎ
−およびＲｓ −Ａｒ −（ＡＯ＞ ｎ −テ示すレル
基〔式中Ｒ５はアルキル基、 Ａｒは芳香環（ベンゼン
環等）、Ａは炭素数１〜４のアルキレン基、ｎは１以上
の整数（１，２，３，・・・・・・）を示す。〕が挙げ
られる。Butyl, hexyl, propenyl, butenyl group: Examples of the aralkyl group which may be aralkyl which may be alkyl-substituted include benzyl group and benzyl group substituted with the above-mentioned alkyl group; acylaminoalkyl,
As acyloxyalkyl and alkoxyalkyl groups,
The group represented by R-Z-A- as described above, and those in which R is replaced with the above-mentioned alkyl group having 1 to 9 carbon atoms: the alkylpolyoxyalkyl group and the alkylarylpolyoxyalkyl group each have the formula Rs (AO)n
- and Rs -Ar - (AO > n - ler group [wherein R5 is an alkyl group, Ar is an aromatic ring (benzene ring, etc.), A is an alkylene group having 1 to 4 carbon atoms, and n is an integer of 1 or more (1, 2, 3,...)] is mentioned.
Ｒ３，Ｒ４の炭素数１〜４のアルキル基、炭素数７〜１
４のアラルキル基としては、前掲のもの；ヒドロキシア
ルキル基としては、ヒドロキシエチル、ヒドロキシプロ
ピル、ヒドロキシブチル基が挙げられる。R3, R4 alkyl group having 1 to 4 carbon atoms, 7 to 1 carbon atoms
Examples of the aralkyl group in No. 4 include those listed above; examples of the hydroxyalkyl group include hydroxyethyl, hydroxypropyl, and hydroxybutyl groups.
アニオン性対イオンＸとしては、ハロゲンイオ”、／
（Ｃ１ｅ、 Ｂｒｅ、 Ｉｅナト） 、 ヒドロキシ
Ａｚイ、ｔン、アルキルサルフェートイオン（ＣＨ３０
ＳＯ３ｅ 。The anionic counter ions X include halogen ions, /
(C1e, Bre, Ie), hydroxy Az, t, alkyl sulfate ion (CH30
SO3e.
Ｃ２Ｈ５０ＳＯ３ｅ ） 、硫酸−ｉ’ ；ｔン（Ｈ３
Ｏ４ｅ 。C2H50SO3e), sulfuric acid-i';t (H3
O4e.
Ｈ３Ｏ３ｅ）、 硝酸イ；ｔン（ＮＯ３ｅ）、 ＣＨ３
ＣＯ０ｅ。H3O3e), nitric acid (NO3e), CH3
CO0e.
ＣＨ３Ｃ６Ｈ４Ｓ０３０． ｃｈ３ｓｏ３ｅ、 Ｈ２
ＰＯ４ｅ。CH3C6H4S030. ch3so3e, H2
PO4e.
ｏｃｏｏｅなどが挙げられる。Ｘのうちで好ましいもの
は、ハロゲンイオンとくにＣ１ｅである。Examples include ocooe. Among X, preferred are halogen ions, particularly C1e.
一般式（１）で示される界面活性剤のうち、好ましいも
のとしては、下記のものがある。Among the surfactants represented by the general formula (1), the following are preferred.
（１）モノ高級アルキル４級アンモニウム塩：（式中、
Ｒは炭素数１０〜２０（好ましくは１０〜１６）のアル
キル基、 Ｒｌ 、 Ｒ＋＋は同一または異なっていて
もよい炭素数１〜３のアルキルおよび／または炭素数２
〜３のヒドロキシアルギル基（好ましくはメチル基＞
ＨＲＩｌｌは炭素数１〜３のアルキル。(1) Monohigher alkyl quaternary ammonium salt: (in the formula,
R is an alkyl group having 10 to 20 carbon atoms (preferably 10 to 16); Rl and R++ are alkyl groups having 1 to 3 carbon atoms and/or 2 carbon atoms, which may be the same or different;
~3 hydroxyargyl groups (preferably methyl groups>
HRIll is alkyl having 1 to 3 carbon atoms.
炭素数２〜３のヒドロキシアルキルまたはベンジル基（
好ましくはメチル、ベンジル基）を示す。〕（１１）ジ
高級アルキル４級アンモニウム塩：（式中、Ｒは炭素数
１０〜２０（好ましくは１０〜１６）のアルキル基；Ｒ
＋ 、 Ｒ＋＋は同一または異なっていてもよい炭素数
１〜３のアルキルおよび／または炭素数２〜３のヒドロ
キシアルキル基（好ましくはメチル基）を示す。〕
本発明の感染防止剤は、一般に、上述のような４級アン
モニウム含有界面活性剤を適当な溶液、たとえば水溶液
、親水性有機溶剤（エタノール。Hydroxyalkyl or benzyl group having 2 to 3 carbon atoms (
(preferably methyl or benzyl group). ] (11) Dihigher alkyl quaternary ammonium salt: (wherein R is an alkyl group having 10 to 20 carbon atoms (preferably 10 to 16);
+ and R++ represent an alkyl group having 1 to 3 carbon atoms and/or a hydroxyalkyl group having 2 to 3 carbon atoms (preferably a methyl group), which may be the same or different. ] The infection preventive agent of the present invention is generally prepared by adding the above-mentioned quaternary ammonium-containing surfactant to a suitable solution, such as an aqueous solution or a hydrophilic organic solvent (ethanol, etc.).
グリコール、グリセリン、ポリエチレングリコールなと
）溶液または水と親水性有機溶剤との混合溶液、好まし
くは水性溶液の形にして、使用される。また、ポリエチ
レングリコール／水混合物でペースト状（軟膏）にして
使用することもできる、溶液またはペースト中の上記界
面活性剤の濃度（固形分当り）は、通常０．０００１〜
ｏ、ｉ重量％。It is used in the form of a solution (such as glycol, glycerin, polyethylene glycol) or a mixed solution of water and a hydrophilic organic solvent, preferably an aqueous solution. The concentration (per solid content) of the surfactant in the solution or paste, which can also be used in the form of a paste (ointment) with a polyethylene glycol/water mixture, is usually 0.0001 to
o, i% by weight.
好ましくはｏ、 ｏｏｉ〜０．０１重量％である。溶液
のｐＨは、用いる界面活性剤の種類により箕なるが、一
般に４〜９好ましくは６〜８とくに好ましくは中性（７
近辺）である。Preferably it is o, ooi to 0.01% by weight. The pH of the solution varies depending on the type of surfactant used, but is generally 4 to 9, preferably 6 to 8, and particularly preferably neutral (7
nearby).
本発明の感染防止剤には、上記界面活性剤に加えて、必
要に応じて、種々の添加剤を加えて、その製品形態等を
改善することができる。例えば、非イオン界面活性剤（
ポリオキシエチレン系非イオン界面活性剤、アルキロー
ルアミド系非イオン界面活性剤など）を加えて洗浄性、
起泡性等を強化することができ、また味覚付与剤（甘味
料、酸味料など）、香料や着色剤（染料、顔料）を加え
て感染防止剤の存在の確認、適用性改善（不快感解消）
等に役立てたりすることができる。In addition to the above-mentioned surfactant, various additives can be added to the infection preventive agent of the present invention, if necessary, to improve the product form and the like. For example, nonionic surfactants (
(polyoxyethylene-based nonionic surfactants, alkylolamide-based nonionic surfactants, etc.) to improve detergency,
It is possible to enhance foaming properties, etc., and by adding taste-imparting agents (sweeteners, acidulants, etc.), fragrances and colorants (dyes, pigments), it is possible to confirm the presence of infection-preventing agents and improve applicability (discomfort). (resolved)
It can be useful for etc.
本発明の感染防止剤は、ソープランドにおいてはソープ
ランド嬢と客との接触があった場合に使用される。接触
によりウィルス感染者（もしくは保有者）と非感染者の
体液交渉によりウィルス感染の危険がある。この体液と
しては血液、精液、唾液、尿、涙などがあり、ウィルス
侵入個所としては男女の性器、直腸、口腔、子宮、その
体の粘膜、血管、皮膚の擦り傷などがある。The infection preventive agent of the present invention is used in soaplands when there is contact between soapland ladies and customers. There is a risk of virus infection due to bodily fluid exchange between a virus-infected person (or carrier) and a non-infected person through contact. These body fluids include blood, semen, saliva, urine, tears, etc., and the places where the virus enters include the genitals, rectum, oral cavity, uterus, mucous membranes, blood vessels, and skin abrasions of men and women.
また、銭湯などにおいては、ウィルス感染者の使った剃
刀や歯ブラシやタオルを使用することにより感染の危険
があり、このような場合に本発明の感染防止剤が使用さ
れる。その使用方法としては、接触を行う前に予め１■
１■ＩＩ■−手を感染防止剤（溶液）に浸漬しておいて
接触を行う方法、接触後に接触部位に感染防止剤を適用
する方法、たとえば感染者（もしくは保有者）の体液の
ついた個所を感染防止剤（溶液）で拭きとる方法、およ
びこれらを組合せた方法をとることができる。Furthermore, in public baths and the like, there is a risk of infection due to the use of razors, toothbrushes, and towels used by people infected with the virus, and the infection preventive agent of the present invention is used in such cases. How to use it: 1.
1■II■ - A method of contact with the hand immersed in an infectious agent (solution), a method of applying an infectious agent to the contact area after contact, for example, a method of applying an infectious agent to the contact area, e.g. A method of wiping the area with an anti-infective agent (solution) or a combination of these methods can be used.
感染防止剤の適用方法としては洗浄、浸漬、塗布。Methods of applying infection control agents include washing, dipping, and painting.
噴霧などが挙げられる。Examples include spraying.
感染防止剤の接触時間は長い方が完全な効果が期待でき
るが、稀薄な溶液（たとえばｏ、 ｏｏｏｉ〜０、００
１重量％濃度）で長時間（たとえば１昼夜〜１週間程度
）接触させてもよく（長時間浸漬できる場合）、比較的
高い濃度（たとえば０．００２〜Ｏ，ＯＳ重量％）で短
時間（たとえば１０秒〜１０分間）接触させてもよい。The longer the contact time with the infection preventive agent, the more complete the effect can be expected, but dilute solutions (e.g.
1% concentration by weight) for a long period of time (e.g. 1 day and night to about 1 week) (if long-term immersion is possible), or a relatively high concentration (e.g. 0.002 to 0.0% by weight of OS) for a short period of time (for example, 1 day and night to 1 week). For example, the contact may be performed for 10 seconds to 10 minutes).
また、感染防止剤の効果は比較的高い温度はど増強され
る。たとえば接触部位に適用する場合、体温ないし４５
℃程度に加温することにより、より短時間で感染が防止
できる。Additionally, the effectiveness of anti-infective agents is enhanced by relatively high temperatures. For example, when applied to the contact area, body temperature or 45%
Infection can be prevented in a shorter period of time by heating to around ℃.
［実施例］ 以下、実施例により本発明をさらに説明するが。[Example] The present invention will be further explained below with reference to Examples.
本発明はこれに限定されるものではない。The present invention is not limited to this.
実施例で使用した界面活性剤は表１の通りである。The surfactants used in the examples are shown in Table 1.
表１
［注１００：オクタデシル： Ｍｅ ：メチル： ＢＺ
：ベンジル：ＤＤニドデシル： ＴＯ：テ゛トラデシ
ル。Table 1 [Note 100: Octadecyl: Me: Methyl: BZ
: Benzyl: DD Nidodecyl: TO: Tetradecyl.
実施例１
界面活性剤工の０．００１及び０．００２重最％水溶液
からなる本発明の感染防止剤を含む銭湯の残り湯（最終
）を対象とした。Example 1 The remaining bath water (final) of a public bath containing the infection preventive agent of the present invention consisting of 0.001% and 0.002% by weight aqueous solutions of surfactant was used.
この残り湯について、下記■、■の方法により、ウィル
ス感染防止効果を試験した。The remaining hot water was tested for virus infection prevention effect using methods ① and ① below.
その結果を表２に示す。The results are shown in Table 2.
■ウィルスに対する効果（１）
上記の残り湯から一般に公知の方法〔参考文献：国立予
防衛生研究所学友金線「ウィルス実験学」、Ｊｏｕｒｎ
ａｌ ｏｆ Ｉｍｍｕｎｏ！ｏｇｙ １０４，２８９（
１９７０） ）でウィルス含有分画を分離し、検体とし
た。ウィルスの足口も公知の方法に準じておこなった（
参考文献二同上）。■Efficacy against viruses (1) Generally known method using the above-mentioned leftover hot water [References: National Institute of Preventive Health Research Student Kinsen "Virus Experiments", Journal
Al of Immuno! ogy 104,289(
(1970)), the virus-containing fraction was separated and used as a specimen. The virus was also removed according to a known method (
Reference 2 (ibid.).
すなわち、ｌ−１８１ａ細胞を用い、直径３Ｃｍのプラ
スチックシャレに単層培養した後、ＰＢＳ緩往ｉ液で３
回洗浄した。That is, using l-181a cells, they were cultured in a monolayer in a plastic dish with a diameter of 3 cm, and then incubated with PBS for 3 hours.
Washed twice.
検体を培地（ＨＥＭ 、子ウシ血清５％、ＮａＨＣＯ３
０，２％）で段階稀釈したちの各１ｍｌおのおののシャ
ーレ中に入れ、３７℃×１時間静置し細胞に吸着させた
。次に前記培地に寒天０．８％を含む寒天培地３ｄを重
層し３７℃で培養した。１００日目ニュートラルレッド
（１：３００００）含む前記寒天培地２ｍｌを更に重層
し３７℃で１日培養後、プラーク数を数えた（５！ａ理
時のプラーク数）。The specimen was transferred to medium (HEM, calf serum 5%, NaHCO3
0.2%) was diluted in stages and 1 ml of each was placed in each Petri dish and allowed to stand at 37°C for 1 hour to be adsorbed to the cells. Next, agar medium 3d containing 0.8% agar was overlaid on the above medium and cultured at 37°C. On the 100th day, 2 ml of the above agar medium containing Neutral Red (1:30000) was further layered, and after culturing at 37°C for 1 day, the number of plaques was counted (number of plaques at 5!a).
また、感染防止剤の代りにＰＢＳ緩衝液のみで浸出した
液についても上記と同様にしてプラーク数を求めた（未
処理時のプラーク数）。これから抑制率（％）を求め、
感染防止効果を見た。In addition, the number of plaques was determined in the same manner as above for the solution leached with only PBS buffer instead of the infection preventive agent (the number of plaques when untreated). Calculate the suppression rate (%) from this,
The effect of preventing infection was observed.
抑制率（％）・（１−０皿＠Ｕ）ｌｙ−’ｙ＊ 、
×１００未処理時のプラーク数
■ウィルスに対する効果（２）
■と同様に検体を別の細胞を用いて測定する。Suppression rate (%) (1-0 dishes @U) ly-'y*,
×100 Number of plaques when untreated ■Effect on viruses (2) Measure the specimen in the same way as in (2) using different cells.
ｙｅｒｏ細胞を用い、■と同様単層培養し、続いて浄し
た。検体を培地（）ｉＥＭ 、子ウシ血清３％）で段階
稀釈したちの各１ｄをおのおののシャーレ中に入れ、３
１℃×１．５時間静置し細胞に吸着させた。Using Yero cells, monolayer culture was carried out in the same manner as in ①, followed by purification. The sample was serially diluted with a medium (iEM, calf serum 3%), and 1 d of each was placed in each Petri dish.
The mixture was allowed to stand at 1°C for 1.5 hours to be adsorbed onto the cells.
次に前記培地に寒天１．０％を含む寒天培地３−を重層
し３７℃で培養した。５日目にニュートラルレッド（１
，：３００００）含む前記寒天培地２ｒＩｄｌを更に重
層し３７℃で２日培養後、プラーク数を数えた、これか
ら抑制率（％）を求め、感染防止効果を見た。Next, agar medium 3- containing 1.0% agar was overlaid on the above medium and cultured at 37°C. Neutral red on the 5th day (1
, :30000) was further layered and cultured at 37°C for 2 days, the number of plaques was counted, and the inhibition rate (%) was determined from this to examine the infection prevention effect.
実施例２，３
界面活性剤工に代えて界面活性剤■または■を用いた他
は、実施例１と同様にして、感染防止剤処理を行い、そ
の効果を試験した。Examples 2 and 3 Infection prevention agent treatment was carried out in the same manner as in Example 1, except that surfactant (1) or (2) was used in place of the surfactant, and the effect thereof was tested.
その結果を表２に示す。The results are shown in Table 2.
表２
［発明の効果コ
本発明の４級アンモニウム含有界面活性剤からなる感染
防止剤は、公衆浴場において、感染者と非感染者の接触
に際し使用することによりウィルスの活性を低下せしめ
ることができ、公衆浴場において感染者と非感染者の接
触の際に起こり得るウィルス性疾患の感染を防止するこ
とができる。Table 2 [Effects of the Invention] The infection preventive agent comprising the quaternary ammonium-containing surfactant of the present invention can reduce virus activity when used in public baths when infected and non-infected people come into contact. It is possible to prevent the spread of viral diseases that can occur when infected and non-infected people come into contact in public baths.
エイズウィルス等のような変異性の高いウィルス性疾患
の有効な治療法の未だ見出されていない現状において、
本発明の感染防止剤は公衆浴場における感染防止に適用
することにより、かかる故意に感染する機会を著しく低
減するという効果を奏する。In the current situation where effective treatments for highly mutable viral diseases such as the AIDS virus have not yet been found,
When applied to the prevention of infection in public baths, the infection prevention agent of the present invention has the effect of significantly reducing the chance of such intentional infection.
Claims (1)
性剤からなる公衆浴場用ウィルス感染防止剤。 ▲数式、化学式、表等があります▼（１） （式中、Ｒ＿１は炭素数８〜２２のアルキル基を有する
有機基；Ｒ＿２はアルキル基、アルキル置換されていて
もよいアラルキル基、アシルアミノアルキル基、アシロ
キシアルキル基、アルコキシアルキル基、アルキルポリ
オキシアルキレン基、またはアルキルアリルポリオキシ
アルキレン基；Ｒ＿３、Ｒ＿４は同一でも異なっていて
もよい炭素数１〜４のアルキル基、炭素数２〜４のヒド
ロキシアルキル基または炭素数７〜１４のアラルキル基
；Ｘはアニオン性対イオンを表す。）２、一般式（１）
中、Ｒ＿１が炭素数１０〜１６のアルキル基；Ｒ＿２、
Ｒ＿３が炭素数１〜３のアルキル基；Ｒ＿４がベンジル
基である、特許請求の範囲第１項記載の感染防止剤。 ３、一般式（１）中、Ｒ＿１、Ｒ＿２が炭素数１０〜１
６のアルキル基；Ｒ＿３、Ｒ＿４が炭素数１〜３のアル
キル基である、特許請求の範囲第１項記載の感染防止剤
。 ４、一般式（１）中、Ｘがハロゲンイオン、ヒドロキシ
ルイオン、アルキルサルフェートイオン、硫酸イオンお
よび硝酸イオンからなる群から選ばれる、特許請求の範
囲第１、２または３項記載の感染防止剤。[Claims] 1. A virus infection preventive agent for public baths comprising a quaternary nitrogen atom-containing surfactant represented by general formula (1). ▲There are mathematical formulas, chemical formulas, tables, etc.▼ (1) (In the formula, R_1 is an organic group having an alkyl group having 8 to 22 carbon atoms; R_2 is an alkyl group, an aralkyl group that may be substituted with alkyl, or an acylaminoalkyl group. group, acyloxyalkyl group, alkoxyalkyl group, alkylpolyoxyalkylene group, or alkylarylpolyoxyalkylene group; R_3 and R_4 are alkyl groups having 1 to 4 carbon atoms, which may be the same or different, and 2 to 4 carbon atoms hydroxyalkyl group or aralkyl group having 7 to 14 carbon atoms; X represents an anionic counterion.) 2, general formula (1)
where R_1 is an alkyl group having 10 to 16 carbon atoms; R_2;
The infection preventive agent according to claim 1, wherein R_3 is an alkyl group having 1 to 3 carbon atoms; R_4 is a benzyl group. 3. In general formula (1), R_1 and R_2 have 10 to 1 carbon atoms
The infection preventive agent according to claim 1, wherein R_3 and R_4 are alkyl groups having 1 to 3 carbon atoms. 4. The infection preventive agent according to claim 1, 2 or 3, wherein in the general formula (1), X is selected from the group consisting of a halogen ion, a hydroxyl ion, an alkyl sulfate ion, a sulfate ion and a nitrate ion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9404987A JPS63258801A (en) | 1987-04-16 | 1987-04-16 | Viral infection inhibitor for public bathhouse |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9404987A JPS63258801A (en) | 1987-04-16 | 1987-04-16 | Viral infection inhibitor for public bathhouse |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS63258801A true JPS63258801A (en) | 1988-10-26 |
Family
ID=14099700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP9404987A Pending JPS63258801A (en) | 1987-04-16 | 1987-04-16 | Viral infection inhibitor for public bathhouse |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS63258801A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995012976A1 (en) * | 1993-11-12 | 1995-05-18 | Bruce Green | Disinfectant composition |
| JP2004083562A (en) * | 2002-07-03 | 2004-03-18 | Asahi Denka Kogyo Kk | Antibacterial agent |
-
1987
- 1987-04-16 JP JP9404987A patent/JPS63258801A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995012976A1 (en) * | 1993-11-12 | 1995-05-18 | Bruce Green | Disinfectant composition |
| JP2004083562A (en) * | 2002-07-03 | 2004-03-18 | Asahi Denka Kogyo Kk | Antibacterial agent |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1168949A (en) | Cleansing compositions | |
| US4975217A (en) | Virucidal composition, the method of use and the product therefor | |
| RU2465891C2 (en) | Antibacterial compositions, products and methods of their application | |
| TW201402150A (en) | Cationic antimicrobial handwash | |
| US20020141959A1 (en) | Antimicrobial skin preparations containing organosilane quaternaries | |
| NZ550744A (en) | Hydrogen peroxide-based skin disinfectant | |
| AU661968B2 (en) | Method for inactivating enveloped viruses and sperm | |
| WO2006013315A1 (en) | Antimicrobial skin composition comprising a biguanide or a quaternium compound | |
| JP2961556B2 (en) | Composition for skin disinfection | |
| US4719235A (en) | Methods and compositions for treating viral infection | |
| EA038526B1 (en) | Antimicrobial composition comprising oligodynamic metal | |
| FI58425B (en) | ANTIMICROBIAL COMPOSITION | |
| JPS63258801A (en) | Viral infection inhibitor for public bathhouse | |
| Lee et al. | Contact dermatitis caused by cetrimide in antiseptics | |
| JPS63255220A (en) | Agent for preventing viral infection for dental use | |
| JPS63258802A (en) | Viral infection inhibitor for public bathhouse | |
| JPS63255202A (en) | Agent for preventing viral infection in public eating house | |
| JPS63264509A (en) | Virus infection inhibitor for eating house | |
| JPS63258412A (en) | Impregnating embrocation for preventing skin contact infection with virus | |
| JPS63264523A (en) | Impregnating and coating agent for preventing skin contact infection by virus | |
| JP7340290B2 (en) | Anti-enveloped virus neutral detergent, disinfectant composition, and method for inactivating enveloped viruses | |
| JPS63258812A (en) | Viral infection inhibitor for dental use | |
| EP3945821B1 (en) | Disinfectant compositions | |
| JP3617760B2 (en) | Detergent composition for atopic dermatitis | |
| JPS63258811A (en) | Viral infection inhibitor for shaving or hairdressing |